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Surgery after failed percutaneous renal
artery angioplasty
James M. Wong, MD, Kimberley J. Hansen, MD, Timothy C. Oskin, MD,
Timothy E. Craven, MSPH, George W. Plonk, Jr, MD, John Ligush, Jr, MD,
and Richard H. Dean, MD, Winston-Salem, NC
Purpose: This retrospective review describes the surgical management of 51 patients after
failed percutaneous renal artery angioplasty (F-PTRA).
Methods: From January 1987 through June 1998, 51 consecutive patients underwent
surgical repair of either atherosclerotic (32 patients) or fibromuscular dysplastic (FMD;
19 patients) renovascular vascular disease after F-PTRA. These patients form the basis
of this report. Surgical repair was performed for hypertension (29 patients with ather-
osclerosis: mean blood pressure, 205 ± 34/110 ± 23 mm Hg; 18 patients with FMD:
mean blood pressure, 194 ± 24/118 ± 18 mm Hg) or ischemic nephropathy (20 patients
with atherosclerosis: mean serum creatinine level, 2.0 ± 0.8 mg/dL; three patients with
FMD: mean serum creatinine level, 2.0 ± 1.1 mg/dL). Emergency operation was
required in four patients for acute renal artery thrombosis (one patient with atheroscle-
rosis, one patient with FMD), renal artery rupture (one patient with atherosclerosis), or
infected pseudoaneurysm (one patient with atherosclerosis). Operative management,
blood pressure and renal function response to operation, and dialysis-free survival rate
were examined and compared with 487 patients (441 patients with atherosclerosis, 46
patients with FMD) treated by operation alone.
Results: Among the patients with atherosclerotic renovascular disease, there were three
postoperative deaths (9.4%) after repair for F-PTRA. Secondary operative repair was asso-
ciated with emergent repair or nephrectomy in 16% of cases, while more extensive renal
artery exposure and more complex operative management was required in 50% of patients
with atherosclerosis and 65% of patients with FMD repaired electively. Among the 28 oper-
ative survivors with hypertension and atherosclerotic renovascular disease, blood pressure
benefit after F-PTRA was significantly lower when compared with patients with athero-
sclerosis who underwent treatment with operation only (57% vs 89%; P < .001). However,
blood pressure benefit in the 19 patients with FMD did not differ (89% vs 96%). Among
the 28 patients with atherosclerosis, preoperative estimated glomerular filtration rate
(EGFR) as compared with postoperative EGFR was significantly increased (47.4 ± 4.2
mL/min/1.73m2 vs 56.6 ± 5.1 mL/min/1.73m2; P = .002). However, EGFR prior 
to PTRA was not significantly different from postoperative EGFR (51.6 ± 3.4
mL/min/1.73m2 vs 56.6 ± 4.9 mL/min/1.73m2; P = .121). As compared with patients
with atherosclerosis who underwent treatment with operation alone, there was no differ-
ence in the dialysis-free survival rate.
Conclusion: Operative repair after F-PTRA was altered in 59% of the patients with ath-
erosclerosis and in 68% of patients with FMD. Blood pressure benefit for patients with
FMD was unchanged after F-PTRA. However, the blood pressure benefit was signifi-
cantly decreased among patients with atherosclerosis. Decreased EGFR after F-PTRA
was recovered with operative renal artery repair. However, postoperative EGFR as com-
pared with EGFR prior to PTRA was unchanged. Blood pressure and renal function
response after F-PTRA for atherosclerotic renovascular disease warrants further study.
(J Vasc Surg 1999;30:468-83.)
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The optimal treatment of renovascular disease
contributing to hypertension or excretory renal insuf-
ficiency is controversial. Since Gruntzig et al1 intro-
duced the technique of percutaneous transluminal
renal artery angioplasty (PTRA) in 1978, the tech-
nique has been widely applied because of its perceived
safety and efficacy.2 Despite the absence of conclusive
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clinical trials, PTRA is considered to be the preferred
treatment for renovascular disease in many centers.2
On the basis of anatomic results that compare favor-
ably with surgical repair, the authors apply PTRA
preferentially to non-ostial atherosclerosis and
uncomplicated medial fibroplasia. However, PTRA
with or without endoluminal stenting has been
Table I. Patients with atherosclerosis: summary of primary presentation and secondary presentation after
failed percutaneous transluminal renal artery angioplasty
Pre-PTRA
Serum Interval from 
creatinine Blood PTRA to 
Patient Age Primary level pressure Secondary operation
no. (year)/sex presentation (mg/dL) (mm Hg) Angiogram* PTRA presentation (months)
1 44/F HTN 1.1 140/95 — Bilat (R · 2) Acute rupture 132,
Emergent
2 48/M HTN 1.0 170/110 R R · 2 HTN 50, 38
3 56/F HTN/IN 2.3 260/130 L ostial L HTN/IN 3
4 56/F HTN/IN 1.3 200/120 R R HTN/IN 6
5 56/M HTN/IN 1.3 160/100 R sup ostial/
L RAB patent R HTN/IN <1
6 57/F HTN/IN 1.4 160/100 R/L occl R HTN/IN 3
7 57/F HTN/IN 1.4 168/94 R ostial/
L occl R (stent) HTN 38
8 58/F HTN 0.9 — Bilat ostial Bilat HTN/IN/DD 10
9 59/F HTN 1.2 190/100 — L HTN 5
10 59/M HTN/IN 1.3 150/90 — L HTN/IN 60
11 60/F HTN 0.8 190/100 Bilat ostial R HTN/
claudication 72
12 60/F HTN/IN 1.3 250/130 R ostial/
L inf ostial L HTN 8
13 60/M HTN 1.0 172/110 Bilat ostial L HTN 69
14 60/M HTN/IN 1.8 240/110 — R HTN/IN 24
15 63/F HTN/IN 1.9 230/130 — L HTN/IN 144
16 63/M HTN 1.2 180/80 Bilat R HTN/IN 5
17 64/M HTN 1.1 170/100 L L HTN 8
18 65/F HTN 0.9 186/100 L ostial L HTN 9
19 65/M HTN/IN 1.9 160/100 Bilat R HTN/IN/DD 4
20 66/M HTN/IN 1.4 200/100 Bilat ostial Bilat HTN/IN 8
21 68/F HTN/IN/CHF 2.0 164/80 R ostial/
L atrophic kidney R · 2 HTN/IN 6, 4
22 68/F HTN 1.0 220/110 R ostial R HTN 6
23 68/F HTN — 180/100 Bilat ostial Bilat (L stent) HTN/IN 19
24 69/F HTN/IN 1.9 — Bilat R HTN/IN 47
25 69/F HTN 1.2 160/80 — R Persist HTN/
tech failure 3
26 70/F HTN/IN 2.4 170/90 L L · 2 HTN/IN 9, 3
27 70/M HTN — 200/90 — Bilat HTN/IN 71
28 72/F IN/CHF 6.6 140/80 R (solitary kidney) R (stent) Infection/ 4
pseudoaneurysm
29 72/M HTN/IN 1.7 180/80 L L HTN/IN 17
30 74/F HTN/IN 1.3 200/100 R ostial/L R HTN/IN 2
31 78/M HTN/IN 4.1 240/130 L L Acute Emergent
thrombosis
32 79/M HTN/IN 1.6 194/108 — R HTN/IN 13
PTRA, Percutaneous transluminal renal artery angioplasty; HTN, hypertension; bilat, bilateral renal arteries; R, right renal artery; IN,
ischemic nephropathy; L, left renal artery; ostial, ostial stenosis; sup, superior renal artery; RAB, renal artery bypass grafting; occl, occlu-
sion; DD, dialysis dependent; inf, inferior renal artery; CHF, congestive heart failure; persist HTN, persistent hypertension; tech failure,
technical failure at PTRA.
*Blank where angiogram results were unavailable.
applied to a variety of other renal artery lesions.2-5
With non-selective application to these other renal
artery lesions, vascular surgeons may be required to
manage recurrent hypertension or excretory renal
insufficiency after failure of PTRA (F-PTRA).
The changes in operative management and out-
come that are attributable to F-PTRA are uncertain.
Early surgical reports that describe significant perivas-
cular inflammation and fibrosis after F-PTRA contrast
with reports from the same time period that attribute
minimal perivascular changes to F-PTRA.6-9 Conse-
quently, we have reviewed our experiences with sec-
ondary surgical intervention after F-PTRA in 51
patients (32 with atherosclerosis, 19 with fibromuscu-
lar dysplasia [FMD]) who underwent treatment at
our institution during the past 11.5 years. Specific
areas of interest included the influence of F-PTRA on
the methods of secondary surgical repair, blood pres-
sure and excretory renal function response to opera-
tion, and follow-up dialysis-free survival rates. Finally,
patients who underwent treatment for F-PTRA were
compared with 487 patients (441 with atherosclero-
sis, 46 with FMD) who underwent treatment with
primary operation alone.
METHODS
Patient population. From January 1987
through June 1998, 576 consecutive patients under-
went operation for renovascular disease at Wake
Forest University Medical Center. Of these patients,
475 underwent treatment for atherosclerosis, 68 for
FMD, 19 for renal artery aneurysms, and 14 for
other renal artery lesions. Of the 475 patients who
underwent treatment for atherosclerotic renovascu-
lar disease, 32 underwent surgical repair after F-
PTRA in 36 renal arteries (Table I). Twenty-five
patients with atherosclerosis had unilateral PTRA,
and seven had bilateral PTRA (including two soli-
tary kidneys). Four patients underwent repeat
PTRA, and three patients underwent renal artery
stent placement. Of the 68 patients with FMD ren-
ovascular disease, 19 underwent operation after F-
PTRA in 21 renal arteries (Table II). Fifteen patients
with FMD underwent unilateral PTRA, and four
underwent bilateral PTRA (including two solitary
kidneys). Two patients with FMD underwent repeat
PTRA prior to operative repair. Five patients (two
with atherosclerosis, three with FMD) underwent
operation for renovascular disease after a prior con-
tralateral PTRA and were excluded from this analy-
sis. Of these 51 patients who underwent repair after
F-PTRA, one third were from our institution and
two thirds were referred.
Patients with atherosclerosis. Patients with 
F-PTRA for atherosclerotic renovascular disease
included 19 women and 13 men (mean age, 61.2 ±
9.5 years; range, 33 to 78 years; Table I). Prior to
PTRA, 31 patients had significant hypertension
(mean blood pressure, 188 ± 32/102 ± 15 mm Hg)
and 19 patients had ischemic nephropathy as defined
by a serum creatinine level (SCr) of 1.3 mg/dL or
more in association with a hemodynamically signifi-
cant renal artery lesion (mean SCr, 2.0 ± 1.3
mg/dL; range, 1.3 to 6.6 mg/dL). After F-PTRA,
three of 32 patients required emergent intervention
for acute renal artery thrombosis, renal artery rup-
ture, or renal artery stent infection with septic
pseudoaneurysm. The remaining 29 patients under-
went elective operation for either recurrent (28
patients) or persistent (one patient) hypertension
(mean preoperative blood pressure, 205 ± 34/110 ±
23 mm Hg; mean medications, 2.5 ± 1.1; Table III).
Twenty patients had ischemic nephropathy after F-
PTRA (mean SCr, 2.0 ± 0.8 mg/dL; range, 1.3 to
4.1 mg/dL [excluding two patients who were dialy-
sis dependent]). Excluding the three emergency
operative procedures, the interval between F-PTRA
and surgical repair ranged from 3 weeks to 12 years
(mean, 24.8 ± 32.6 months; median, 9 months).
Patients with fibromuscular dysplasia. Patients
with F-PTRA for FMD renovascular disease included
18 female patients and one male patient (mean age,
32.8 ± 16.1 years; range, 5 to 62 years; Table II).
Prior to PTRA, all 19 patients had significant hyper-
tension (mean blood pressure, 184 ± 30/112 ± 17
mm Hg) and no patient had ischemic nephropathy
(mean SCr, 1.0 ± 0.3 mg/dL; range, 0.8 to 1.2
mg/dL). One of the 19 patients required emergent
operation for acute renal artery thrombosis. The
remaining 18 patients underwent elective operation
for either recurrent (15 patients) or persistent (three
patients) hypertension (mean preoperative blood
pressure, 194 ± 24/118 ± 18 mm Hg; mean medica-
tions, 1.9 ± 1.2; Table IV). Three patients had
ischemic nephropathy after F-PTRA (mean SCr, 2.0 ±
1.1 mg/dL; range, 1.3 to 3.3 mg/dL). Excluding the
emergency operation, the interval between F-PTRA
and surgical repair ranged from 6 days to 4 years
(mean interval, 11.1 ± 14.2 months; median, 5
months).
Patient evaluation. Among the 29 patients
with atherosclerosis who underwent elective opera-
tion for F-PTRA, preoperative renal angiography
was performed with either conventional (25
patients) or digital subtraction (one patient) tech-
niques (Table III). Failure was represented by recur-
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rent stenosis (26 renal arteries), persistent stenosis
(one renal artery), thrombosis (six renal arteries),
pseudoaneurysm (two renal arteries, including one
mycotic pseudoaneurysm), or dissection (one renal
artery). Bilateral renovascular disease was present in
20 patients, and renal artery atherosclerosis was con-
sidered ostial in 21 patients. Significant aortic dis-
ease was noted in six patients (two abdominal aortic
aneurysms, four occlusive disease). Renal vein renin
assays were obtained in 11 patients with atheroscle-
rosis before surgery. Lateralization of renin activity
was observed in seven patients. Of the remaining 22
patients with atherosclerosis, three underwent emer-
gency operations and 12 had bilateral renal artery
disease (including one with a solitary kidney).
Among the 18 patients with FMD who under-
went elective operation for F-PTRA, preoperative
renal angiography was performed by either conven-
tional (16 patients) or digital subtraction (two
patients) techniques (Table IV). Failure was repre-
sented by recurrent stenosis (11 renal arteries), per-
sistent stenosis (three renal arteries), dissection
(three renal arteries), thrombosis (two renal arter-
ies), macroaneurysm (two renal arteries), or an arte-
riovenous fistula (one renal artery). Six patients had
bilateral renal artery involvement (including two
solitary kidneys), and nine patients had branch renal
artery disease. Renal vein renin assays lateralized in
seven of 11 patients. Of the remaining eight
patients, two had bilateral disease and two had soli-
tary kidneys.
Operative findings and surgical repair. Forty-
three atherosclerotic kidneys were surgically repaired,
32 were repaired after F-PTRA, and an additional 11
contralateral renal arteries without PTRA were
repaired simultaneously (Table III). In addition,
seven nephrectomies were performed (four after a
prior F-PTRA) for a total of 50 procedures. Bilateral
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Table II. Patients with fibromuscular dysplasia: summary of primary presentation and secondary presenta-
tion after failed percutaneous transluminal renal artery angioplasty
Pre-PTRA
Serum Interval from 
creatinine Blood PTRA to 
Patient Age Primary level pressure Secondary operation
no. (year)/sex presentation (mg/dL) (mm Hg) Angiogram* PTRA presentation (months)
33 6/F HTN — — — bilat HTN 6
34 6/F HTN — 175/100 bilat L persist HTN/ < 1
tech failure
35 23/F HTN 1.0 190/140 L (br) L (br) acute
thrombosis emergent
36 23/F HTN 0.4 165/100 R (br, R (br) HTN/IN 5
solitary kidney)
37 24/M HTN 1.2 176/110 L sup (aneurysm) L (br) persist 11
HTN/IN
38 24/F HTN — — R R HTN 3
39 25/F HTN 1.1 170/110 — L HTN 9
40 26/F HTN — 142/96 R (br) R (br) · 2 HTN 42, 3
41 27/F HTN 1.0 170/114 L L HTN 2
42 31/F HTN 0.8 200/110 L (solitary kidney) L HTN 2
43 33/F HTN — 170/100 R (br) R (br) HTN 49
44 36/F HTN 1.2 200/110 R/L R HTN/IN 3
hypoplastic
kidney
45 38/F HTN — 285/160 — R HTN 1
46 44/F HTN 0.7 180/120 L sup L HTN 26
47 49/F HTN 0.9 190/110 R (br)/L L HTN 2
48 51/F HTN — — — L HTN 19
49 53/F HTN 0.9 178/114 R (br)/L bilat (R br) persist HTN/ 5
tech failure
50 60/F HTN 1.2 180/106 R (br) R HTN 11
51 62/F HTN 1.1 170/90 R (br)/L sup R (br) · 2 HTN 4, 3
PTRA, Percutaneous transluminal renal artery angioplasty; HTN, hypertension; bilat, bilateral renal arteries; L, left renal artery; persist
HTN, persistent hypertension; tech failure, technical failure at PTRA; br, branch renal artery; R, right renal artery; IN, ischemic
nephropathy; sup, superior renal artery.
*Blank where angiogram results were unavailable.
Table III. Patients with atherosclerosis: preoperative summary and result of secondary surgical repair
Preoperative
Serum Secondary
Patient creatinine level Blood pressure surgical
no. (mg/dL) (mm Hg) Angiogram* procedure†
1 0.8 140/80 R ostial (pseudoaneurysm) R RAB, repair pseudoaneurysm
2 0.9 190/120 R R RAB, IMA reconstruct
3 2.0 262/130 L ostial (dissection) L RIM
4 1.3 233/140 R R RIM
5 1.3 166/100 R sup ostial/L RAB patent R RAB
6 1.5 190/110 — R RIM, L RAB
7 1.1 220/120 R (stent)/L occl R RAB, L nephrectomy
8 3.4/DD 168/94 Bilat ostial Bilat RAB
9 0.9 240/120 L occl L RAB
10 3.5 198/110 R ostial/L occl R RAB, L nephrectomy
11 0.7 240/140 Bilat ostial Bilat RAB, Aortobifem
12 1.2 270/172 R ostial/L inf ostial R REA, L RAB
13 1.1 210/136 R RAB patent/L RA occl L RAB
14 2.9 172/88 R occl/L R nephrectomy, L RAB (ex vivo)
15 2.0 180/90 L (solitary kidney) L RAB (splenorenal)
16 1.6 204/86 Bilat R RAB, L REA
17 1.0 170/96 L L RIM
18 1.0 200/71 L ostial R REA, L RIM
19 8.2/DD 200/80 MR angio: bilat flow R nephrectomy, L REA
20 1.7 240/120 Bilat ostial Bilat RAB
21 2.2 190/95 R ostial (inf br occl) R RAB, L nephrectomy, AAA
22 1.2 182/92 R ostial R RAB
23 1.3 240/100 Bilat ostial (L stent) R REA, L RAB
24 1.8 262/112 Bilat Bilat REA
25 1.0 200/82 R ostial/L occl R RIM, L nephrectomy
26 2.0 240/130 L L RAB (splenorenal)
27 2.8 200/98 Bilat ostial (br) Bilat RAB
28 0.9 140/80 R (stent) pseudoaneurysm Axbifem, R RAB, debrid infxn
29 1.6 180/100 L L RAB
30 1.5 200/80 R ostial/L Bilat REA
31 4.1 240/130 L occl R REA, L nephrectomy
32 1.3 208/108 R R RAB
F-PTRA, Failed percutaneous transluminal renal artery angioplasty; R, right renal artery; ostial, ostial stenosis; RAB, renal artery bypass 
grafting; IMA, inferior mesenteric artery; br, branch renal artery; L, left renal artery; RIM, renal artery reimplantation; sup, superior 
renal artery; occl, occlusion; bilat, bilateral renal arteries; aortobifem, aortobifemoral bypass grafting; inf, inferior renal artery; REA,
renal artery endarterectomy; RA, renal artery; ex vivo, ex vivo renal artery bypass grafting; splenorenal, splenorenal bypass; postop,
postoperative; MR angio, magnetic resonance angiography; DD, dialysis dependent; AAA, abdominal aortic aneurysm; axbifem,
axillobifemoral bypass grafting; debrid infxn, operative debridement of infected tissue.
*Blank where angiogram results were unavailable.
†RAB was aortorenal bypass grafting unless otherwise indicated.
‡A prePTRA angiogram not available to judge.
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procedures were performed in 20 patients (including
two patients with solitary kidneys), and unilateral pro-
cedures were performed in 12 patients. Aortorenal
bypass grafting was performed in 25 instances (21
saphenous vein, four polytetraflouroethylene),
splenorenal bypass grafting in two, and an ex vivo
bypass graft in one. Renal artery reimplantation was
performed in six instances. Ten renal artery throm-
boendarterectomies were performed by either trans-
renal (nine instances) or transaortic (one instance)
techniques. Combined aortic reconstruction was per-
formed in three patients (one abdominal aortic
aneurysm, one occlusive disease, one infection).
Secondary operative repair after F-PTRA was consid-
ered altered by the requirement for emergent inter-
vention (three patients, including one requiring
nephrectomy) or nephrectomy of a previously recon-
structable kidney (three additional patients). In addi-
tion, secondary elective repair was considered altered
if periarterial fibrosis or inflammation needed a
change in operative management (six patients).
Finally, the requirement for distal branch renal artery
repair after F-PTRA that would not have been need-
ed for primary repair as indicated by angiographic
anatomy (10 patients, including three with associated
periarterial fibrosis) was also considered to have
increased operative complexity. In all, secondary
repair was considered altered in 19 patients with ath-
erosclerosis (59%).
Twenty-one kidneys with FMD were surgically
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repaired, 19 renal arteries were repaired after F-
PTRA, and two contralateral arteries without PTRA
were simultaneously repaired (Table IV). In addition,
two nephrectomies were required after F-PTRA for a
total of 23 procedures. Bilateral procedures were per-
formed in six patients (including two patients with
solitary kidneys), and unilateral procedures were per-
formed in 13 patients. Renal artery bypass grafting
was performed in 20 instances (16 saphenous vein,
three hypogastric artery, and one polytetraflouroeth-
ylene graft), including four ex vivo bypass grafts. One
transrenal renal artery thromboendarterectomy was
performed for atherosclerotic renovascular disease.
Branch renal artery repair was required in 16
instances. Secondary operative repair was considered
altered in 13 patients with FMD (68%) after F-PTRA.
Nephrectomy was required in two patients (one
emergently), and periarterial fibrosis resulted in a
more difficult dissection and prolonged operation in
five patients. Including three of these five patients,
more distal branch renal artery exposure and recon-
struction was required in nine patients, necessitating
four branch ex vivo repairs.
Histologic evaluation of the involved renal artery
showed medial fibroplasia in 12 patients (three with
secondary intimal fibrosis), intimal fibroplasia in two
patients, and perimedial dysplasia in three patients.
Histology was unavailable in two patients.
Statistical methods. Summary statistics (ie,
means, standard deviations, etc, of continuous data
Postoperative
Effect of F-PTRA Serum
on operative creatinine level Blood pressure
management (mg/dL) (mm Hg) Outcome
Yes: acute rupture 0.8 120/72 Alive
Yes: control secondary br/fibrosis 0.8 140/80 Alive
None 1.8 180/100 Died
None 1.3 170/120 Alive
Yes: control primary br 0.7 148/82 Alive
‡ 1.2 182/102 Alive, L RAB occl
Yes: periarterial fibrosis 1.8 140/70 Alive
None 0.7 140/80 Alive
‡ 0.8 140/90 Alive/L nephrectomy
Yes: nephrectomy 4.1 130/76 Died
Yes: control primary br 0.7 112/88 Died
Yes: control primary br 1.1 162/82 Alive
Yes: control primary br 0.8 160/100 Died
Yes: nephrectomy 2.4 150/70 Died/DD
None — — Died postop
Yes: control primary br 1.5 150/80 Alive
None 0.9 130/84 Alive
None 1.0 140/80 Alive
Yes: dissection into br/nephrectomy 4.6 160/80 Alive/DD
Yes: periarterial fibrosis 1.1 160/90 Alive
None 1.6 170/66 Alive
Yes: control primary br/fibrosis 1.1 140/60 Alive
Yes: control beyond stent 1.3 180/90 Alive
None — — Died postop
None 1.0 160/70 Died
Yes: control primary br/fibrosis 1.6 140/70 Died
‡ 3.1 160/85 Died
Yes: infected stent/pseudoaneurysm 0.8 140/80 Alive
Yes: control primary br 1.1 120/80 Died
None 1.3 105/60 Alive
Yes: nephrectomy — — Died postop/DD
Yes: periarterial fibrosis 1.3 175/105 Alive
Table IV. Patients with fibromuscular dysplasia: preoperative summary and result of secondary surgical repair
Preoperative
Serum Secondary Effect of F-PTRA
Patient creatinine level Blood pressure surgical on operative
no. (mg/dL) (mm Hg) Angiogram procedure† management
33 0.5 220/110 R/L (br) Bilat RAB None
34 0.5 175/109 Bilat R RAB, L REA Yes: control primary br
35 1.0 190/140 L occl L nephrectomy Yes: nephrectomy
36 3.3 180/105 R (br, solitary kidney) R RAB (ex vivo) Yes: (ex vivo)
37 1.4 176/100 L sup occl L nephrectomy Yes: nephrectomy
38 0.9 200/100 R (br/dissection) R RAB Yes: control primary br/fibrosis
39 0.9 150/110 L (br/AVF) L RAB *
40 1.0 180/100 R (br) R RAB (ex vivo) Yes: periarterial fibrosis (ex vivo)
41 1.2 200/120 L L RAB Yes: periarterial fibrosis
42 1.0 220/130 L (solitary kidney) L RAB (ex vivo) Yes: periarterial fibrosis (ex vivo)
43 0.6 210/140 R (br) R RAB None
44 1.3 170/110 R/L hypoplastic kidney R RAB Yes: control primary br
45 0.9 240/160 R (br) R RAB *
46 0.7 210/140 L sup L RAB Yes: control tertiary br
47 1.1 180/94 R (br)/L (dissection) Bilat RAB Yes: L control primary br
48 1.0 170/120 R RAB patent/L L RAB None
49 0.9 220/120 R (br)/L Bilat RAB None
50 1.2 220/130 R (br/aneurysm) R RAB Yes: periarterial fibrosis
51 1.2 170/100 R (diss/aneurysm)/L sup R RAB (ex vivo) Yes: (ex vivo)
F-PTRA, Failed percutaneous transluminal renal artery angioplasty; R, right renal artery; L, left renal artery; br, branch renal artery;
bilat, bilateral renal arteries; RAB, renal artery bypass grafting; int fib, secondary intimal fibrosis; REA, renal artery endarterectomy; 
occl, occlusion; ex vivo, ex vivo renal artery bypass grafting; sup, superior renal artery; AVF, arteriovenous fistula; diss, intimal dissection; 
neph, nephrectomy.
*A prePTRA angiogram not available to judge.
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and frequencies and relative frequencies of categorical
data) were calculated, and the data were examined to
verify that the assumptions of statistical tests were
met. All the patient group comparisons were stratified
by renal artery disease type (atherosclerotic or FMD).
Statistical comparison of patient demographic charac-
teristics between F-PTRA and operative repair–only
groups was performed for categorical factors with
Fisher exact test for two-way contingency tables and
for continuous factors with unpaired t tests. Fisher
exact test was used to assess significance of differences
between these groups in graded renal function and
hypertension responses to surgical intervention and to
test for between-group differences in perioperative
mortality.
With the application of the modified formula of
Cockroft and Gault,10 the values of SCr were trans-
formed to a calculated measure of estimated glomeru-
lar filtration rate (EGFR; mL/min/1.73m2): EGFR =
[(140 – age)(weight)/(72)(SCr)] · [1.73/BSA],
where BSA is body surface area. BSA was calculated by
BSA = [height (cm)]0.725 · [weight (kg)]0.425 ·
0.007184. For female patients, EGFR was multiplied
by 0.85 to correct for gender differences in muscle
mass and average rate of creatinine synthesis.
Statistical assessment of within-group EGFR
responses to operation was made with paired t tests,
and between-group comparisons of EGFR were
made with analysis of covariance that controlled for
preoperative EGFR levels. Analysis of pre-PTRA lev-
els to preoperative to postoperative changes in
EGFR for atherosclerotic patients for whom PTRA
failed were performed with maximum-likelihood,
repeated measures, analysis of covariance.11,12 This
technique allowed for the inclusion of two patients
whose pre-PTRA EGFR levels were not obtainable.
Graphic depiction of dialysis-free survival was
made with product-limit estimates of event-free fol-
low-up periods. For patients with atherosclerosis,
tests for differences in dialysis-free survival between
F-PTRA and operative repair–only groups were per-
formed with log-rank test.
RESULTS
Operative morbidity and mortality. There
were three in-hospital deaths (9.4%) among the 32
patients with atherosclerosis after operative interven-
tion as a result of cerebrovascular accidents (n = 2)
and multisystem organ failure (n = 1). Renal-related
morbid events occurred in four patients with athero-
sclerosis, including thrombosis of renal artery repair
(two patients) and suture-line hemorrhage (two
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patients). One patient required graft thrombectomy
and temporary hemodialysis for acute renal failure.
Extra-renal morbid events that prolonged hospital-
ization occurred in nine patients with atherosclerosis
(28%). These events included cardiac dysrhythmia
(five patients), pneumonia (two patients), and pul-
monary edema (two patients).
In a mean follow-up period of 42.3 ± 37.8
months, nine additional atherosclerotic deaths
occurred (Table III). Two of these patients had dial-
ysis-dependent end-stage renal disease develop. A
third patient remains alive on dialysis. In all, three
patients with atherosclerosis became dialysis depen-
dence. These three patients represent three of four
patients (75%) who required nephrectomy after F-
PTRA. Late graft thrombosis (3%) occurred in one
patient at 15 months.
Although the proportion of atherosclerotic
patients treated for F-PTRA progressing to either
death or dialysis dependence was significantly
greater than the patients who underwent treatment
with operative repair alone (death or dialysis depen-
dence, 40.6% vs 20.5%; P = .013), this difference
reflected a different mean follow-up period between
the two groups (follow-up, 42.3 ± 37.8 months vs
28.3 ± 27 months). By product-limit estimate, there
was no difference in follow-up death or dialysis
dependence (P = .668; Fig 1). However, when con-
sidering only patients with atherosclerosis who
required nephrectomy, there was a significantly
Postoperative
Serum
Surgical creatinine level Blood pressure
pathology (mg/dL) (mm Hg) Outcome
Medial fibroplasia (int fib) 0.5 100/70 Died
Medial fibroplasia (int fib) 0.6 124/86 Alive
Intimal fibroplasia 1.3 118/90 Alive
Perimedial dysplasia 1.1 140/85 Alive
— 1.3 140/108 Alive
Medial fibroplasia 0.8 160/90 Alive
Medial fibroplasia 0.9 130/80 Alive
Intimal fibroplasia 1.0 130/90 Alive
Medial fibroplasia 0.9 140/76 Alive
Medial fibroplasia 0.9 124/74 Alive
Medial fibroplasia (int fib) 0.6 110/80 Alive
Perimedial dysplasia 0.6 140/80 Alive
Perimedial dysplasia 0.8 140/100 Alive
Medial fibroplasia 0.6 170/110 Alive
— 0.8 112/80 Alive
Medial fibroplasia (int fib) 0.9 150/90 Alive
Medial fibroplasia 0.7 160/96 Alive
Medial fibroplasia 1.1 142/86 Alive
Medial fibroplasia 1.2 160/70 Alive/R neph
Fig 1. Product-limit estimates of time to death or dialy-
sis, with and without prior percutaneous transluminal
renal artery angioplasty (PTRA).
Table V. Comparison of operative intervention after failed percutaneous transluminal renal artery angio-
plasty and primary operative intervention (patients with atherosclerosis)
Primary operative Secondary operative intervention 
intervention only (n = 441) after F-PTRA (n = 32) P value
Perioperative mortality 4.3% 9.4% NS
Hypertension response
Cured 11% 7% <.001
Improved 78% 50%
No change 11% 43%
Renal function response (preop SCr, >1.3 mg/dL)
Improved 47% 41% NS
No change 43% 59%
Worsened 10% 0
Eventual dialysis dependence 7.2% 9.4% NS
Follow-up death rate 18.4% 37.5% .018*
F-PTRA, Failed percutaneous transluminal renal artery angioplasty; NS, no significant difference; preop SCr, preoperative serum creati-
nine level.
*Differences were not significant with life-table analysis.
Table VI. Comparison of operative intervention after failed percutaneous transluminal renal artery angio-
plasty and primary operative intervention (patients with fibromuscular dysplasia)
Primary operative Secondary operative intervention 
intervention only (n = 46) after F-PTRA (n = 19) P value
Hypertension response
Cured 29% 31% NS
Improved 67% 58%
No change 4% 11%
Renal function response
(preop SCr, >1.3 mg/dL)
Improved 78% 66% NS
No change 22% 33%
Worsened 0 0
F-PTRA, Failed percutaneous transluminal renal artery angioplasty; NS, no significant difference; preop SCr, preoperative serum
creatinine level.
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greater incidence of dialysis dependence after F-
PTRA as compared with operative repair alone (dial-
ysis dependence, 75% vs 10%; P < .001).
There were no 30-day or in-hospital deaths
among the 19 patients with FMD. Thrombosis of
renal artery repair occurred in one patient (5%).
Extra-renal morbid events occurred in two patients
(cardiac dysrhythmia [n = 1], and pulmonary edema
[n = 1]). At a mean follow-up period of 55.6 ± 41.3
months, no patient with FMD progressed to dialysis
dependence, although one patient did die (5%).
There have been no late graft failures (Table IV).
Blood pressure response. Blood pressure and
medication requirements at least 1 month after sec-
ondary operative intervention were used to define
blood pressure response.13 With the application of
these criteria to 28 operative survivors with athero-
sclerotic renovascular disease and hypertension, two
patients (7%) were considered cured, 14 patients
(50%) were improved, and 12 patients (43%) were
failed (Table V). As compared with patients who
underwent treatment with operative repair only, F-
PTRA was associated with significantly decreased
blood pressure benefit (57% vs 89%; P < .001).
Among the 19 patients with FMD who under-
went treatment for F-PTRA, six patients (31%) were
considered cured, 11 patients (58%) were improved,
and two patients (11%) were failed (Table VI). As
compared with patients who underwent treatment
with operative repair only, there was no difference in
either cure or blood pressure benefit after F-PTRA
(89% vs 96%; P = .576).
Renal function response. A significant change
in excretory renal function was defined as a change in
SCr of 20% or more obtained at least 3 weeks after
operative repair. Patients were classified as improved if
they were removed from dialysis or if their SCr
decreased by 20% or more. Patients were classified as
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worsened if their SCr increased by 20% or more. All
the other patients were considered to have no change.
With the application of these criteria to the 17
operative survivors with atherosclerotic renovascular
disease with preoperative SCr of 1.3 mg/dL or more,
seven patients (41%) were considered improved,
including one patient who was removed from dialysis
dependence. Ten patients (59%) were unchanged. As
compared with patients who underwent treatment
with operative repair only, the proportion of patients
with improved renal function after surgery was simi-
lar (P = .804; Table V).
When considering all 28 operative survivors
with atherosclerotic renovascular disease and F-
PTRA, preoperative EGFR as compared with post-
operative EGFR was significantly increased (47.4 ±
4.2 mL/min/1.73m2 vs 56.6 ± 5.1 mL/min/
1.73m2; P = .002; Table VII). With the application
of model-based estimates of EGFR to allow for 
the inclusion of two patients without EGFR data,
there was no significant change in EGFR prior to
balloon dilatation as compared with preoperative 
EGFR (51.6 ± 3.4 mL/min/1.73m2 vs 47.4 ± 3.9
mL/min/1.73m2; P = .152; Table VIII) or postop-
erative EGFR (51.6 ± 3.4 mL/min/1.73m2 vs 56.6
± 4.9 mL/min/1.73m2; P = .121).
Table IX compares the demographic features
and the operative management of these 32 patients
with atherosclerosis who underwent operation after 
F-PTRA with the 441 patients who underwent
treatment with operation alone. With the exception
of a lower prevalence of associated aortic disease
among the patients with F-PTRA (P < .001), there
was no difference between the two groups.
Interestingly, among the patients with F-PTRA,
EGFR prior to balloon dilatation was significantly
different from preoperative EGFR in patients who
underwent treatment with operation alone (51.8 ±
3.4 mL/min/1.73m2 vs 41.3 ± 1.3 mL/min/
1.73m2; P < .001). In terms of operative manage-
ment, among the 36 kidneys that were treated after
F-PTRA as compared with the 684 kidneys that
were treated with operation alone, the rate of renal
artery bypass grafting, ex vivo repair, and nephrec-
tomy was similar. However, the rate of renal 
artery reimplantation (P = .04) and renal artery
Table VII. Comparison of change in preoperative estimated glomerular filtration rate to postoperative
estimated glomerular filtration rate after failed percutaneous transluminal renal artery angioplasty versus
operation only (patients with atherosclerosis)
Preoperative EGFR Postoperative EGFR Adjusted postoperative EGFR
Group No. (mL/min/1.73m2) (mL/min/1.73m2) (mL/min/1.73m2)
F-PTRA 28 47.4 ± 4.2 ‹ P = .002fi 56.6 ± 5.1 51.7 ± 3.1
› ›
P = .206 P = .254
fl fl
Operation only 355 41.3 ± 1.3 ‹ P < .001fi 47.6 ± 1.4 48.2 ± 0.9
EGFR, Estimated glomerular filtration rate; F-PTRA, failed percutaneous transluminal renal artery angioplasty.
Table VIII. Comparison of estimated glomerular filtration rate for patients with atherosclerosis with failed
percutaneous transluminal renal artery angioplasty
Procedure: PrePTRA Preoperative Postoperative
PTRA/ EGFR ± SE EGFR ± SE EGFR ± SE 
operative repair No. (mL/min/1.73m2) (mL/min/1.73m2) P value† (mL/min/1.73m2) P value‡
Overall 28 51.6 ± 3.4* 47.4 ± 3.9 .152 56.6 ± 4.9 .121
Unilateral/unilateral 11 48.4 ± 5.3 51.4 ± 6.2 .486 63.3 ± 7.8 .005
Unilateral/bilateral 12 50.7 ± 5.1 44.1 ± 6.0 .122 45.7 ± 7.5 .282
Bilateral/unilateral 1 68.7 ± 17.7 94.5 ± 20.7 — 94.5 ± 26 —
Bilateral/bilateral 4 58.6 ± 10.2* 34.6 ± 10.3 .232 61.1 ± 13 .79
PTRA, Percutaneous transluminal renal artery angioplasty; EGFR, estimated glomerular filtration rate; SE, standard error.
*Modeled EGFR.
†prePTRA EGFR versus preoperative EGFR.
‡prePTRA EGFR versus postoperative EGFR.
P = .012 for overall: preoperative EGFR versus postoperative EGFR.
Table IX. Comparison of patients with and without prior failed percutaneous transluminal renal artery 
angioplasty (n = 538)
Patients with atherosclerosis (n = 473)
Secondary operative
Primary operative intervention
intervention only after F-PTRA P value
Sex
Male 226/441 (51%) 13/32 (41%) NS
Female 215/441 (49%) 19/32 (59%)
Age (years)
Mean 63.9 (± 9.5) 63.5 (± 7.9) NS
Range 30 to 86 44 to 79
Mean SBP/DBP (mm Hg) 198 (± 36)/103 (± 21) 205 (± 34)/110 (± 23) NS
Preop duration of HTN (months) 117 (± 106) 147 (± 123) NS
Preop EGFR* 41.3 ± 1.3 47.4 ± 4.2 NS
Primary intervention
Combined aortic repair 194/441 (44%) 3/32 (9%) <.001
Bilateral RA repair 241/441 (55%) 20/32 (63%) NS
No. of kidneys
Ex vivo 5/361 (1.4%) 1/23 (0.03%) NS
RAB 361/684 (53%) 23/36 (64%) NS
REA 228/684 (33%) 3/36 (8%) <.001
RIM 47/684 (7%) 6/36 (17%) .042
Nephrectomy 49/684 (7%) 4/36 (11%) NS
Preop azotemia (SCr, >1.8 mg/dL) 212/437 (49%) 11/32 (34%) NS
Diabetes mellitus 62/419 (15%) 7/32 (22%) NS
CHF 83/441 (18%) 7/32 (22%) NS
Angina/myocardial infarction 172/441 (39%) 11/32 (34%) NS
TIA/CVA 92/414 (22%) 11/32 (34%) NS
FMD, Fibromuscular dysplasia; F-PTRA, failed percutaneous transluminal renal artery angioplasty; NS, no significant difference; SBP,
systolic blood pressure; DBP, diastolic blood pressure; preop, preoperative; HTN, hypertension; EGFR, estimated glomerular filtration 
rate (in mL/min/1.73m2); RA, renal artery; RAB, renal artery bypass grafting; REA, renal artery endarterectomy; RIM, renal artery 
reimplantation; SCr, serum creatinine level; CHF, congestive heart failure; TIA, transient ischemic attack; CVA, cerebral vascular accident.
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thromboendarterectomy were significantly differ-
ent (P < .001).
Three of the 19 patients with FMD repaired after 
F-PTRA had preoperative renal insufficiency. With
the application of the renal function response crite-
ria described previously, two patients were consid-
ered improved after secondary operative repair
(Table VI). Among all 19 patients with FMD, the
improvement in preoperative EGFR as compared
with postoperative EGFR was significant (88 ± 9.1
mL/min/1.73m2 vs 99.7 ± 7.5 mL/min/1.73m2;
P = .019). Table IX compares the demographic fea-
tures and the operative management of these 19
patients with FMD repaired after F-PTRA with the
46 patients who underwent treatment operation by
alone. There were no differences between the two
groups.
DISCUSSION
Our experience with 51 patients who underwent
surgical treatment after F-PTRA demonstrated that
emergency repair or nephrectomy was required in
16% while more extensive renal artery exposure and
more complex operative management was required
in 50% of patients with atherosclerosis and 65% of
patients with FMD repaired electively. Blood pres-
sure benefit was decreased after operation for F-
PTRA in patients with atherosclerotic renovascular
disease as compared with treatment with primary
operation alone. However, response among patients
with FMD was equivalent. Compared with excreto-
ry renal function after F-PTRA, there was a signifi-
cant increase in renal function after surgical repair
of F-PTRA. However, as compared with renal func-
tion before percutaneous dilatation, there was no
change. Nevertheless, the secondary perioperative
mortality and dialysis-free survival rate was similar
to patients who underwent treatment with primary
repair alone.
Reports that describe the results of operative
repair after F-PTRA are few in number. In 1983,
Guzzetta et al6 described the surgical management of
three pediatric patients after F-PTRA. Since this ini-
tial report, three additional groups have described
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the surgical management of 75 patients after F-
PTRA. Dean et al7 described perivascular inflamma-
tion in each of nine cases. The complexity of recon-
struction was considered to be affected by F-PTRA
in five of 12 procedures. In addition, five patients had
significant deterioration in renal function after F-
PTRA that was recovered with surgical repair. In
contrast, two other reports have attributed minimal
effects to prior F-PTRA.8,9 McCann et al8 described
their experience with 13 patients (eight with athero-
sclerosis, five with FMD) after F-PTRA. Although
five of 13 patients required emergency operation and
two of 13 reconstructions failed, the authors con-
cluded that surgical repair was not complicated by F-
PTRA. As a group, mean blood pressure improved in
response to repair after F-PTRA. However, renal
function response was not addressed. In addition,
Martinez et al9 described their experience with 53
patients (36 with atherosclerosis, and 17 with FMD)
who underwent repair after F-PTRA. Of their
patients, 17% had only a guidewire passed, without
an attempt at balloon dilatation, and an additional
44% demonstrated immediate elastic recoil after
dilatation. Only 11 patients underwent surgical
repair for recurrent renal artery stenosis. Blood pres-
sure benefit was observed in 93% of their patients,
and postoperative renal function was considered to
be improved in 79% of the 28 patients with ischemic
nephropathy. Despite the fact that emergency repair
was required for eight patients and nephrectomy was
required in three instances, only one of 50 repairs
was considered to be technically complicated as a
result of F-PTRA.
In contrast, our experience with operative man-
agement after F-PTRA was characterized by periar-
terial fibrosis and increased complexity of repair. Of
the balloon dilatations described in this experience,
80% were considered to be an immediate technical
success, with recurrence months after the initial 
percutaneous treatment. In the case of atherosclero-
sis, initial success of PTRA is often associated with
focal dissection of the renal artery lesion and 
the disruption of the internal elastic lamina.14
Similar to spontaneous renal artery dissection, these
Patients with FMD (n = 65)
Secondary operative
Primary operative intervention
intervention only after F-PTRA P value
10/46 (22%) 1/19 (5%) NS
36/46 (78%) 18/19 (95%)
39.4 (± 17.6) 33.7 (± 16.1) NS
7 to 70 6 to 62
186 (± 34)/112 (± 22) 194 (± 24)/118 (± 18) NS
105 (± 143) 81 (± 102) NS
87.1 ± 5.9 88 ± 9.1 NS
1/46 (2%) 0 NS
13/46 (28%) 6/19 (32%) NS
22/51 (43%) 4/18 (22%) NS
51/60 (85%) 18/21 (86%) NS
2/60 (3%) 1/21 (5%) NS
5/60 (8%) 0 NS
2/60 (3%) 2/21 (9%) NS
1/46 (2%) 1/19 (5%) NS
0 1/19 (5%) NS
1/46 (2%) 0 NS
2/46 (4%) 1/19 (5%) NS
3/46 (6%) 0 NS
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events are frequently associated with early perivascu-
lar inflammation and eventual periarterial fibrosis.
Alternatively, percutaneous treatment after an inabil-
ity to cross a renal artery lesion and elastic recoil may
not be associated with this perivascular response.
Regardless of the presence of these perivascular
changes, we consider the requirement for more dis-
tal branch renal artery repair after F-PTRA and
emergent renovascular procedures for rupture or
thrombosis to be increased in complexity.
Few of these patients presented after F-PTRA in
combination with endoluminal stents. However,
such failures can be anticipated. Of the three patients
in this study who underwent repair after endolumi-
nal stent placement, all underwent treatment for
atherosclerotic renovascular disease during the final
2 years of the study period. In each instance, the
endoluminal stent increased the complexity of renal
artery reconstruction. In addition to the septic
pseudoaneurysm reported in this study, endoluminal
stents effectively exclude renal artery thromboen-
darterectomy and reimplantation as surgical options.
Moreover, our limited experience with reoperation
for failed endoluminal stents showed intense periar-
terial fibrosis consistent with focal renal artery dis-
section. Despite a high initial technical success rate,
renal artery stenting for ostial atherosclerotic reno-
vascular disease has a reported restenosis rate that
ranges from 13% to 65%.3,15-20 More importantly,
the long-term functional outcome of renal artery
PTRA with and without stenting is uncertain.
Published results, however, do not support an
improvement in functional outcome equivalent to
those observed with primary surgical reconstruction.
Among the patients with atherosclerotic renovas-
cular disease, this experience demonstrated decreased
blood pressure benefit after operative repair for F-
PTRA when compared with primary surgical inter-
vention alone. However, the explanation for this dif-
ference is uncertain. Perhaps patients were selected for
PTRA without a causal relationship between the renal
artery lesion and hypertension. Alternatively, the
observed result may reflect the limitations of surgical
repair, PTRA, or both. Failed balloon angioplasty was
associated with branch renal artery exposure and
more distal, branch renal artery reconstruction. As the
complexity of branch repair increases, our center’s
technical failure rate also increases.13 Moreover, our
primary method of intraoperative assessment and
postoperative surveillance (ie, renal duplex sonogra-
phy) has shown poor overall accuracy for branch renal
artery repair as compared with main renal artery
reconstruction.13,21 Although failure of secondary
surgical repair was detected infrequently (3%), branch
disease contributing to hypertension may have been
underestimated.
Conversely, the eventual blood pressure response
after secondary operative repair of atherosclerotic
renovascular disease may reflect limitations of
PTRA. Although considered an immediate technical
success in 80% of instances, hemodynamic assess-
ment of percutaneous treatment was performed
infrequently. Angiographic appearance may correlate
poorly with residual pressure gradient or evaluation
with intravascular ultrasound scanning.22 In addi-
tion, percutaneous dilatation may be associated with
distal atheroembolization.23 By creating occlusion
and activation of the renin-angiotensin axis at the
microvascular level, renal artery repair may fail to
provide blood pressure benefit. Indirect support for
this last mechanism is provided by the blood pres-
sure response observed among patients with FMD.
Although branch renal artery repair was necessitated
in 76% of the patients after F-PTRA, the eventual
blood pressure response was equivalent to that of
patients with FMD who underwent treatment with
surgical reconstruction alone.
Unfortunately, an assessment of initial renal func-
tion response after PTRA was impossible because renal
function data were not routinely obtained after percu-
taneous dilatation. Nevertheless, when compared with
EGFR before secondary operative repair, initial renal
function declined after F-PTRA. Although surgical
repair led to a significant increase in excretory renal
function, as compared with renal function prior to
PTRA, there was no change. Whether patients who
underwent treatment after F-PTRA should be consid-
ered improved or unchanged with regard to renal
function is not certain. However, this distinction may
have importance when the change in EGFR after
intervention is compared with the subsequent decline
in excretory function and the progression to dialysis-
dependence. With the consideration of all patients
with atherosclerosis who underwent treatment at our
center since January 1987, only those patients with a
significant (ie, ‡ 20%) increase in EGFR after surgical
renal artery repair have demonstrated a significant
decrease in the rate of decline in renal function and a
significant and independent increase in dialysis-free
survival.24-27 Patients whose renal function remained
unchanged have demonstrated a relative risk of follow-
up dialysis dependence and death equivalent to
patients whose renal function worsened after
surgery.13,24,25,27 In light of these observations, the
common practice of reporting unchanged renal func-
tion as “preserved” after renovascular intervention is
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misleading.24 Patients with ischemic nephropathy that
remains unchanged after intervention do not enjoy
“preserved” renal function but remain at increased risk
for eventual dialysis dependence and death.
Given the apparent association between renal func-
tion response and dialysis-free survival, issues of func-
tion response should be considered carefully in the
selection of the method of renal artery intervention. In
this regard, the liberal use of PTRA with endoluminal
stenting has helped clarify its role as a therapeutic
option in the treatment of renovascular disease. The
available data argue for its selective application in
patients with atherosclerosis and ischemic nephropa-
thy. Reports that describe the results of endoluminal
stenting for renovascular disease report blood pressure
benefit in 31% to 100% of patients with a variety of cri-
teria.3,15-20 However, these same reports described less
reliable improvement in renal function (range, 0 to
36%), while restenosis was observed in 13% to 65% of
patients. Despite the limitations of a direct comparison
between reports of PTRA and surgical therapy, endo-
luminal stenting of ostial atherosclerosis does not
appear to yield renal function benefit equivalent to pri-
mary surgical management. Accordingly, PTRA is
applied selectively at our center. Non-ostial atheroscle-
rotic lesions of the main renal artery and FMD lesions
of the medial fibroplasia type that are free of branch
renal artery involvement are considered to be optimal
lesions for balloon dilatation. Otherwise, PTRA is con-
sidered for suboptimal lesions in patients who demon-
strate significant and independent parameters associat-
ed with decreased survival (ie, clinical congestive heart
failure, advanced diabetes mellitus, and uncorrectable
azotemia).13
Because this study was retrospective, inherent
limitations make certain comparisons complex.
These include the comparison of patients with dif-
fering indications for intervention and uncertain
functional significance of the original renovascular
lesion. In addition, the variable time interval
between angioplasty, failure, and secondary surgi-
cal therapy, the wide-range in follow-up period,
and the absence of data regarding initial functional
outcome are also limitations. Nevertheless, this
review provides information regarding long-term
results of operative intervention after F-PTRA and
demonstrates the need for careful patient selection
and continued patient follow-up.
In summary, failure of PTRA was associated
with emergency repair or nephrectomy in 16% of
patients and complex elective operative manage-
ment in one half to two thirds of patients. Given
the increased operative complexity and comorbid-
ity encountered in this patient population, F-
PTRA is best managed by experienced renovascu-
lar surgeons. For patients with atherosclerotic ren-
ovascular disease, blood pressure benefit was sig-
nificantly decreased after F-PTRA. However, renal
function was often restored to levels observed
before balloon dilatation. Although selection bias-
es inherent to this retrospective report limit the
power of these observations, this experience
increases our enthusiasm for the study of PTRA as
compared with surgical repair for renovascular dis-
ease associated with hypertension and excretory
renal insufficiency.
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DISCUSSION
Dr Thomas C. Naslund (Nashville, Tenn). Dr Wong
and his colleagues from Wake Forest have described their
11.5-year experience with surgical management of failed
percutaneous transluminal renal artery angioplasty. They
have offered comparison with the outcome of their exten-
sive experience with patients managed with surgical thera-
py alone. These data show reduced blood pressure benefit
from surgical renal revascularization after failed angioplas-
ty as compared with patients managed with surgical revas-
cularization. The reduced benefit in blood pressure con-
trol was realized in patients with atherosclerotic renal
artery disease but not with fibromuscular dysplasia.
Furthermore, this report documents that surgical
revascularization with patients who have a failed angio-
plasty tends to be more complicated than with patients
undergoing primary surgical revascularization. It also rais-
es the possibility that this complexity of operation may
reduce the benefit in the antihypertensive arena. Also, the
possibility of microembolic complication is raised as a
potential etiology for reduced operative benefit.
As noted by the authors, the practice of renal artery
balloon angioplasty has become first-line therapy for the
treatment of renal artery lesions in some centers. This
practice also may be associated with no effort to show
physiologic significance of renal artery lesions before
angioplasty. Therefore, on encountering a failed renal
artery angioplasty outcome, one may be faced with uncer-
tainty as to whether or not the original lesion ever had
physiologic significance. If the original angioplasty
involved an asymptomatic lesion, later surgical revascular-
ization might be ineffective.
In the manuscript of this report, renal vein renin assays
were done in 11 patients with atherosclerotic disease
before operation. However, an additional 11 patients, by
my interpretation, would have unilateral disease but had
either no physiologic tests or nonlateralizing results.
Considering the small sample size, a lack of documented
physiologic significance in 11 out of 28 atherosclerotic
patients might explain the observed poorer blood pressure
control after operation.
I would like to ask Dr Wong three questions. First, is
the proportion of negative physiologic testing or no phys-
iologic testing similar in the primary operative revascular-
ization group and in the group of failed balloon angio-
plasty?
Second, do you have any information regarding the
frequency of physiologic testing in the atherosclerotic
patients before balloon angioplasty?
And third, should patients with failed renal angioplas-
ty and negative physiologic tests be considered good can-
didates for surgical revascularization to control blood
pressure?
I would like to thank Dr Wong and his colleagues for
their report and their continued interest in the excellent
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management of renovascular disease. I appreciate the
opportunity to review the manuscript and discuss this
paper.
Dr James M. Wong. Thank you, Dr Naslund, for your
insightful comments.
In regards to your first question, one of the inherent
difficulties with this retrospective review is the fact that, as
you mentioned, unilateral angioplasties were performed in
many patients who then required bilateral operative
repairs. The assessment of the response to angioplasty and
the response to repair when we did repair both sides in the
absence of renal function determination is difficult.
Several of our patients required emergency proce-
dures, as noted, and this left very few elective patients that
had unilateral disease without renal vein renin assays.
Among the patients that did have assays, the beneficial
blood pressure response, when they lateralized, was equiv-
alent to that observed in the entire group.
We did not have information regarding renal vein
renin assays before balloon angioplasty among the major-
ity of the patients. This data was limited.
And finally, patients presenting with negative physio-
logic tests–that is, nonlateralizing renins and recurrent,
unilateral renal artery disease after a failed renal artery
angioplasty—are not optimal candidates for secondary
repair. However, these are the minority of patients. Most
presented after failed angioplasty with either severe hyper-
tension and bilateral renal artery disease or hypertension
with renal insufficiency. In these cases, physiologic testing
is not always mandatory. 
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